US HB4640 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 12-0)
Status: Introduced on October 11 2019 - 25% progression, died in committee
Action: 2019-10-14 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on October 11 2019 - 25% progression, died in committee
Action: 2019-10-14 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.
Title
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019
Sponsors
| Rep. Peter DeFazio [D-OR] | Rep. Lloyd Doggett [D-TX] | Rep. Ro Khanna [D-CA] | Sen. Peter Welch [D-VT] |
| Rep. Mark Pocan [D-WI] | Rep. Janice Schakowsky [D-IL] | Rep. Rosa DeLauro [D-CT] | Rep. Raul Grijalva [D-AZ] |
| Rep. Steve Cohen [D-TN] | Rep. Marcy Kaptur [D-OH] | Rep. Chellie Pingree [D-ME] | Rep. Jesus Garcia [D-IL] |
History
| Date | Chamber | Action |
|---|---|---|
| 2019-10-14 | House | Referred to the Subcommittee on Health. |
| 2019-10-11 | House | Referred to the House Committee on Energy and Commerce. |
| 2019-10-11 | House | Introduced in House |
Subjects
Drug safety, medical device, and laboratory regulation
Health
Health programs administration and funding
Health technology, devices, supplies
Inflation and prices
Intellectual property
Medical research
Research and development
Health
Health programs administration and funding
Health technology, devices, supplies
Inflation and prices
Intellectual property
Medical research
Research and development
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/house-bill/4640/all-info |
| Text | https://www.congress.gov/116/bills/hr4640/BILLS-116hr4640ih.pdf |
